Health Knowledge, Attitudes, Practice, Health Personnel Attitude
Conditions
Keywords
Healthcare Professionals, Health Personnel Knowledge, Attitudes, Practices, Healthcare Skills and Training, Human Papillomavirus Vaccination, Human Papillomavirus Cancer Screening, HPV Cancer Prevention, HPV Cancer Mitigation, Sexual and Reproductive Health, U.S.-Mexico Border Health, Behavioral Research, Community Engaged Research, Health Disparities, Health Inequities, Social Determinants of Health, Coronavirus disease 2019 (COVID-19) Pandemic
Brief summary
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV). Our hypothesis is that improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among the populations they serve.
Detailed description
A sample of emerging \[in training\] and current \[in practice\] health professionals from the El Paso U.S.-Mexico Border Region will be recruited to participate in a human papillomavirus (HPV) educational and professional skills intervention. Hypothesis: improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among eligible individuals through a tailored multi-media intervention to strengthen providers' ability to discuss HPV and vaccination in an informed and culturally competent manner, and increase subsequent provider recommendations.
Interventions
BEHAVIORALTailored HPV Education and Professional Skills Intervention Group
The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
BEHAVIORALGeneral HPV Education and Communication Skills Control Group
The general provider education intervention will involve audio and visual content and will be delivered in the English language.
Sponsors
University of Texas, El Paso
National Institute on Minority Health and Health Disparities (NIMHD)
Burrell College of Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
* Participants \[blinding\]: participants will be randomly assigned to treatment and control groups, they will not be made aware of other participant's receipt of treatment or control materials. Participants will be asked not to discuss this project outside of the intervention; delivery of the intervention or other educational materials will be virtual, limiting the ability of participants to interact with one another during the study. * Outcome assessor \[blinding\]: to reduce bias in the implementation and assessment of the clinical trial, participant information and pre-post survey responses will be maintained separately from the assignment and delivery of the intervention.
Intervention model description
A parallel trial design will be used to examine the effectiveness of a tailored HPV education and professional skills intervention. Emerging and current healthcare providers will be randomly assigned to one of two conditions: 1) treatment condition in which they will receive a tailored Education and Professional Skills Intervention, and 2) control condition in which they will receive general, publicly available information about HPV and communication skills. Participants will then be followed over time and the responses will be compared between groups.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Current (in practice) or emerging (in training - medical student, resident, or fellow) healthcare provider * Working/training or living in the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico) * Have the authorization to recommend/prescribe/administer the HPV vaccine
Exclusion criteria
* Unaffiliated with the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico) * Participation in Phases I or II of the larger research project \[cross-sectional phases\] * Does not identify as a current or emerging healthcare provider * Declines or is unable to participate in the full intervention and follow-up time-points * Unable to complete participation and activities in the English language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Healthcare Provider (HCP) Practices Scale Score | Baseline | Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5). Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Human Papillomavirus (HPV) Attitude Score | Immediately post-intervention (0 months). | Healthcare provider (HCP) attitudes toward HPV and the HPV vaccine. The 9-item HPV Vaccine Attitudes scale assessed perceived safety, perceived harm, and perceived effectiveness of the HPV vaccine. Items were rated on a 5-point Likert scale ranging from Strongly disagree (1) to Strongly agree (5). A composite score was calculated by averaging responses across all assessed items, ranging from 1 to 5, with higher scores indicating more positive attitudes toward HPV vaccination. |
| Human Papillomavirus (HPV) Knowledge Score | Immediately post-intervention (0 months). | Healthcare provider (HCP) knowledge about HPV and the HPV vaccine was assessed using post-intervention scores from the Human Papillomavirus (HPV) Knowledge Scale included in the healthcare personnel survey. The 14-item HPV Knowledge scale consisted of True/False items scored as True (1) or False (0). A composite score was calculated by averaging responses across all assessed items and multiplying the result by 100 to obtain a percentage score, ranging from 0 to 100, with higher scores indicating greater HPV-related knowledge. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATOREva M Moya, PhD, LMSW
The University of Texas at El Paso, Border Biomedical Research Center
Participant flow
Recruitment details
Recruitment took place via face-to-face and electronic invitation to healthcare providers in practice or in training in West Texas (El Paso County) and Southern New Mexico (mainly Dona Ana County). Access to the survey and intervention was provided via weblink or QR code. Initial recruitment to the clinical trial took place from 12/22/2023 through 05/13/2024. Only participants completing the initial survey and intervention were allowed to complete the 3- and 6-month post-intervention surveys.
Pre-assignment details
161 participants were enrolled for the study; 24 participants subsequently voluntarily withdrew and 137 were randomly assigned to one of the study groups: Control (general communication intervention; n=75) or Treatment (targeted educational intervention; n=62).
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 3 Participants |
| Age, Categorical Between 18 and 65 years | 116 Participants |
| Age, Continuous | 32.0 Years STANDARD_DEVIATION 9.84 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 29 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 22 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 14 Participants |
| Race (NIH/OMB) White | 81 Participants |
| Sex: Female, Male Female | 35 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
None listed